Life SciencesPharmaceuticalsTherapeutic AreaDermatology

Atopic Dermatitis: Global Drug Forecast and Market Analysis to 2027

Lowest Prices Guaranteed Length Publisher Published Date SKU
from $10,995 108 Pages GlobalData November, 2018 GBDT15898915
Lowest Prices Guaranteed
Price from $10,995
Length 108 Pages
Publisher GlobalData
Published Date November, 2018
SKU GBDT15898915

Atopic Dermatitis: Global Drug Forecast and Market Analysis to 2027

Summary

Global sales in the atopic dermatitis market are expected to grow to $18.3B by 2027, at a Compound Annual Growth Rate (CAGR) of 11.1% from 2017-2027. It is estimated that sales of drugs in the atopic dermatitis market were approximately $6.4B in 2017 in the 7MM (United States, France, Germany, Italy, Spain, United Kingdom and Japan).

The US was the largest market, with approximately $5.1B in drug sales, which represented 80% of the total atopic dermatitis market. The 5EU market contributed $1.1B in sales and Japan contributed sales of $202M in 2017. It is forecasted that the US to grow to $13.6B, followed by 5EU (France, Germany, Italy, Spain, United Kingdom) and Japan.

Atopic dermatitis is a widespread chronic inflammatory skin condition that can affect patients of all ages and is the result of a complex interplay of environmental, immunological, genetic, and pharmacologic factors. The atopic dermatitis market has historically remained stagnant and the pipeline for drugs in late-stage development was lacking, but recent developments have reignited interest in the treatment of the disease, especially as the estimated drug-treated population may grow to 24,000,000 people over the next decade.

The atopic dermatitis pipeline has traditionally been focused on topical therapies, with Pfizer’s Eucrisa being the latest to be approved in December 2016. Until the launch of Regeneron/Sanofi’s Dupixent in March 2017, severe atopic dermatitis patients had to be prescribed systemic immunomodulators, which are associated with a slew of side effects. However, the arrival of Dupixent, a first-in-class monoclonal antibody (mAb), addressed the unmet needs of these severe patients. The pipeline mostly comprises systemic therapies targeting the moderate-to-severe population.

The report Atopic Dermatitis: Global Drug Forecast and Market Analysis to 2027, provides key metrics for atopic dermatitis (Epidemiology, Market Size, Product Pipeline, Key Events, Competitive Analysis) in the seven major pharmaceutical markets (7MM) covered in this report-the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan-during the forecast period from 2017-2027.

Key Questions Answered

  • The projected entry of pipeline agents such as the Interleukin inhibitors and the JAK inhibitors during the forecast period is expected to spur intense growth within the atopic dermatitis market. How do products compete against each other? Which of these drugs will have the highest peak sales, and why?
  • Key Opinion Leaders (KOLs) interviewed by GlobalData have indicated that there are considerably high unmet needs within the atopic dermatitis indication. What are the main unmet needs in this market? How can the pharmaceutical industry address these needs? To what degree will the therapies under development fulfill these unmet needs?
  • The atopic dermatitis market is likely to remain a dynamic, growing space throughout the forecast period and beyond. Which companies are set to be major players in atopic dermatitis during the forecast period?
Scope
  • Overview of atopic dermatitis including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized atopic dermatitis therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2017 and forecast for ten years to 2027.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the atopic dermatitis therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global atopic dermatitis therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy

The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global atopic dermatitis therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global atopic dermatitis therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global atopic dermatitis therapeutics market from 2017-2027.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Atopic Dermatitis: Executive Summary
2.1 Atopic Dermatitis Market to Experience Strong Growth from 20172027
2.2 Late-Stage Pipeline Product Launches Will Result in New Players Establishing Themselves
2.3 Persistent Unmet Needs Will Be Addressed Over the Forecast Period
2.4 Interleukin Inhibitors and Janus Kinase Inhibitors Dominate the Atopic Dermatitis Pipeline
2.5 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification or Staging Systems
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast Assumptions and Methods - Population
5.4.3 Forecast Assumptions and Methods - One-Year Total and Diagnosed Prevalent Cases of Atopic Dermatitis
5.4.4 Forecast Assumptions and Methods - One-Year Total Prevalent Cases of Atopic Dermatitis by Severity
5.4.5 Forecast Assumptions and Methods - One-Year Diagnosed Prevalent Cases of Atopic Dermatitis by Severity
5.5 Epidemiological Forecast for Atopic Dermatitis (20172027)
5.5.1 One-Year Total Prevalent Cases of Atopic Dermatitis
5.5.2 Age-Specific One-Year Total Prevalent Cases of Atopic Dermatitis
5.5.3 Sex-Specific One-Year Total Prevalent Cases of Atopic Dermatitis
5.5.4 One-Year Total Prevalent Cases of Atopic Dermatitis by Severity
5.5.5 One-Year Diagnosed Prevalent Cases of Atopic Dermatitis
5.5.6 Age-Specific One-Year Diagnosed Prevalent Cases of Atopic Dermatitis
5.5.7 Sex-Specific One-Year Diagnosed Prevalent Cases of Atopic Dermatitis
5.5.8 One-Year Diagnosed Prevalent Cases of Atopic Dermatitis by Severity
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of the Analysis
5.6.3 Strengths of the Analysis
6 Disease Management
6.1 Diagnosis and Treatment Overview
6.2 US
6.3 5EU
6.4 Japan
7 Competitive Assessment
7.1 Overview
8 Unmet Needs and Opportunity Assessment
8.1 Overview
8.2 Topical Treatments Without Side Effects
8.3 A Drug that Effectively Controls Patients’ Pruritus
8.4 Addressing Heterogeneity in the Pathophysiology of Atopic Dermatitis
8.5 Improved Patient Compliance and Education
9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Company Profiles
10.3.1 LEO Pharma
10.3.2 Pfizer
10.3.3 Regeneron
10.3.4 AbbVie
10.3.5 Dermira
10.3.6 Eli Lilly
10.3.7 Galderma
10.3.8 Incyte
10.4 Other Players
11 Market Outlook
11.1 Global Markets
11.1.1 Forecast
11.1.2 Drivers and Barriers - Global Issues
11.2 US
11.2.1 Forecast
11.2.2 Key Events
11.2.3 Drivers and Barriers
11.3 5EU
11.3.1 Forecast
11.3.2 Key Events
11.3.3 Drivers and Barriers
11.4 Japan
11.4.1 Forecast
11.4.2 Key Events
11.4.3 Drivers and Barriers
12 Appendix
12.1 Bibliography
12.2 Abbreviations
12.3 Methodology
12.3.1 Forecasting Methodology
12.3.2 Diagnosed Patients
12.3.3 Percent Drug-Treated Patients
12.3.4 Drugs Included in Each Therapeutic Class
12.3.5 Launch and Patent Expiry Dates
12.3.6 General Pricing Assumptions
12.3.7 Individual Drug Assumptions
12.3.8 Generic Erosion
12.3.9 Pricing of Pipeline Agents
12.4 Primary Research - Key Opinion Leaders and Payers Interviewed for This Report
12.4.1 Key Opinion Leaders
12.4.2 Payers
12.5 Primary Research - Prescriber Survey
12.6 About the Authors
12.6.1 Analyst
12.6.2 Reviewer
12.6.3 Therapy Area Director
12.6.4 Epidemiologist
12.6.5 Managing Epidemiologists
12.6.6 Global Director of Therapy Analysis and Epidemiology
12.6.7 Global Head and EVP of Healthcare Operations and Strategy
12.7 About GlobalData
12.8 Contact Us
12.9 Disclaimer
1.1 List of Tables
Table 1: Atopic Dermatitis: Key Metrics in the 7MM
Table 2: Risk Factors and Comorbid Conditions Associated with Atopic Dermatitis
Table 3: Treatment Guidelines for Atopic Dermatitis
Table 4: Country Profile - US
Table 5: Country Profile - 5EU
Table 6: Country Profile - Japan
Table 7: Leading Treatments for Atopic Dermatitis, 2017
Table 8: Comparison of Therapeutic Classes in the Development for Atopic Dermatitis, 2017-2027
Table 9: LEO Pharma’s Atopic Dermatitis Portfolio Assessment, 2018
Table 10: Pfizer’s Atopic Dermatitis Portfolio Assessment, 2018
Table 11: Regeneron’s Atopic Dermatitis Portfolio Assessment, 2018
Table 12: AbbVie’s Atopic Dermatitis Portfolio Assessment, 2018
Table 13: Dermira’s Atopic Dermatitis Portfolio Assessment, 2018
Table 14: Eli Lilly’s Atopic Dermatitis Portfolio Assessment, 2018
Table 15: Galderma’s Atopic Dermatitis Portfolio Assessment, 2018
Table 16: Incyte’s Disease Portfolio Assessment, 2018
Table 17: Atopic Dermatitis Market - Global Drivers and Barriers, 2017-2027
Table 18: Key Events Impacting Sales for Atopic Dermatitis in the US, 2017-2027
Table 19: Atopic Dermatitis Market - Drivers and Barriers in the US, 2017-2027
Table 20: Key Events Impacting Sales for Atopic Dermatitis in the 5EU, 2017-2027
Table 21: Atopic Dermatitis Market - Drivers and Barriers in the 5EU, 2017-2027
Table 22: Key Events Impacting Sales for Atopic Dermatitis in Japan, 2017-2027
Table 23: Atopic Dermatitis Market - Global Drivers and Barriers in Japan, 2017-2027
Table 24: Key Projected Launch Dates for Atopic Dermatitis
Table 25: Key Historical and Projected Patent Expiry Dates for Atopic Dermatitis
Table 26: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
1.2 List of Figures
Figure 1: Global Sales Forecast by Country for Atopic Dermatitis in 2017 and 2027
Figure 2: Analysis of the Company Portfolio Gap in Atopic Dermatitis During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Atopic Dermatitis During the Forecast Period
Figure 4: Major Drug Targets for Atopic Dermatitis Treatment
Figure 5: 7MM, Age-Standardized One-Year Total Prevalence of Atopic Dermatitis (%), Both Sexes, All Ages, 2017
Figure 6: 7MM, Sources Used and Not Used to Forecast the One-Year Total and Diagnosed Prevalent Cases of Atopic Dermatitis
Figure 7: 7MM, Sources Used to Forecast the One-Year Total Prevalence by Severity of Atopic Dermatitis
Figure 8: 7MM, Sources Used to Forecast the One-Year Diagnosed Prevalent Cases by Severity of Atopic Dermatitis
Figure 9: 7MM, One-Year Total Prevalent Cases of Atopic Dermatitis, Both Sexes, All Ages, N, 2017
Figure 10: 7MM, Age-Specific One-Year Total Prevalent Cases of Atopic Dermatitis, Both Sexes, All Ages, N, 2017
Figure 11: 7MM, Sex-Specific One-Year Total Prevalent Cases of Atopic Dermatitis, All Ages, N, 2017
Figure 12: 7MM, One-Year Total Prevalent Cases of Atopic Dermatitis by Severity, Both Sexes, All Ages, N, 2017
Figure 13: 7MM, One-Year Diagnosed Prevalent Cases of Atopic Dermatitis, Both Sexes, All Ages, N, 2017
Figure 14: 7MM, Age-Specific One-Year Diagnosed Prevalent Cases of Atopic Dermatitis, Both Sexes, All Ages, N, 2017
Figure 15: 7MM, Sex-Specific One-Year Diagnosed Prevalent Cases of Atopic Dermatitis, All Ages, N, 2017
Figure 16: 7MM, One-Year Diagnosed Prevalent Cases by Severity of Atopic Dermatitis, Both Sexes, All Ages, N, 2017
Figure 17: Flowchart of the Diagnosis and Management of Atopic Dermatitis
Figure 18: Unmet Needs and Opportunities in Atopic Dermatitis
Figure 19: Overview of the Development Pipeline in Atopic Dermatitis
Figure 20: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for Atopic Dermatitis in the 7MM During the Forecast Period
Figure 21: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Atopic Dermatitis During the Forecast Period
Figure 22: Analysis of the Company Portfolio Gap in Atopic Dermatitis During the Forecast Period
Figure 23: Global (7MM) Sales Forecast for Atopic Dermatitis by Country in 2017 and 2027
Figure 24: Sales Forecast for Atopic Dermatitis by Class in the US in 2017 and 2027
Figure 25: Sales Forecast for Atopic Dermatitis in the 5EU by Class in 2017 and 2027
Figure 26: Sales Forecast for Atopic Dermatitis by Class in Japan in 2017 and 2027

$10,995
$21,990
$32,985
 
Research assistance
US: 800.298.5699
Int'l: +1.240.747.3093
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks